Dietary and endogenous ligands compete with drugs for receptor occupancy and therefore should be considered during therapeutic interventions and during pharmacokinetic/ pharmacodynamic modeling. When disease is the result of an overabundance of these natural ligands, antibodies and/or their Fab fragments may be useful as therapeutic agents to reverse the effects of the natural ligands.